Evidence map›Paper›PMID 30144150›Full record

ArticleAmerican journal of hematology2018

Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease.

Julia Z Xu, Melanie E Garrett, Karen L Soldano, Sean T Chen, Clary B Clish, Allison E Ashley-Koch, Marilyn J Telen

Open access · bronzeAbstract read
In one paragraph

Article in American journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Alterations of Plasma Metabolites Associated with Sickle Cell Trait.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Observational
  9. Management of Kidney Disease with Sickle Cell Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Julia Z XuDepartment of Medicine, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0003-4147-8388
Melanie E GarrettDepartment of Medicine, Division of Nephrology and Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0003-2302-6150
Karen L SoldanoDepartment of Medicine, Division of Nephrology and Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.
Sean T ChenDuke University School of Medicine, Durham, North Carolina.
Clary B ClishMetabolite Profiling, Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.ORCID 0000-0001-8259-9245
Allison E Ashley-KochDepartment of Medicine, Division of Nephrology and Duke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-5409-9155
Marilyn J TelenDepartment of Medicine, Division of Hematology and Duke Comprehensive Sickle Cell Center, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0003-3809-1780
Duke Medical Center · USDuke University · USBroad Institute · US

Funding

Pulmonary Hypertension in SCDR01HL079915 · NHLBI · DUKE UNIVERSITY · PI TELEN, MARILYN J · 2005 to 2008
$6.7M
Outcome Modifying Genes in Sickle Cell DiseaseR01HL068959 · NHLBI · DUKE UNIVERSITY · PI TELEN, MARILYN J · 2001 to 2005
$3.6M
Transcriptomic, therapeutic and genetic investigations of sickle cell nephropathyR01DK110104 · NIDDK · DUKE UNIVERSITY · PI ASHLEY-KOCH, ALLISON E, DAVIS, ERICA ELLEN · 2016 to 2018
$716k
Broad InstituteDoris Duke Charitable Foundation 2015131Hubert-Yeargan Center for Global Health, Duke UniversityNHLBI NIH HHS R01 HL068959NHLBI NIH HHS R01 HL079915NIDDK NIH HHS R01 DK110104
6 · The paper itself

Abstract

Sickle cell disease (SCD) nephropathy and lower estimated glomerular filtration rate (eGFR) are risk factors for early mortality. Furthermore, rate of eGFR decline predicts progression to end-stage renal disease in many clinical settings. However, factors predicting renal function decline in SCD are poorly documented. Using clinical, laboratory, genetic, and metabolomic data, we evaluated predictors of renal function decline in a longitudinal cohort of 288 adults (mean age 33.0 years). In 193 subjects with 5-year follow-up data, mean rate of eGFR decline was 2.35 mL/min/1.73 m

Indexed as

Disease ProgressionGlomerular Filtration RateAdultAnemia, Sickle CellCreatinineFemaleHumansMaleRenal Insufficiency, ChronicRisk AssessmentRisk FactorsCreatinine

Identifiers

PMID30144150
PMCPMC6397774
OpenAlexW2888667032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.